Neuroone Medical Technologies Corp在提交给美国证券交易委员会（SEC）的文件中表示，公司计划于本季度晚些时候正式推出Stereoced平台，该平台将用于开展人体试验性临床研究。这一消息标志着该公司在医疗技术领域迈出了关键一步，为其后续的临床开发奠定了基础。
Neuroone Medical Technologies Corp在提交给美国证券交易委员会（SEC）的文件中表示，公司计划于本季度晚些时候正式推出Stereoced平台，该平台将用于开展人体试验性临床研究。这一消息标志着该公司在医疗技术领域迈出了关键一步，为其后续的临床开发奠定了基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.